Through selective reaction monitoring/multi-reaction monitoring (SRM/MRM), EphA2 on urinary EVs presents significant expression differences between patients with bladder cancer/non-malignant hematuria and healthy controls. The gene discussed is EPHA2; the disease is urinary bladder carcinoma.